Key statistics
On Friday, Artiva Biotherapeutics Inc (ARTV:NMQ) closed at 4.00, 172.11% above the 52 week low of 1.47 set on Jun 27, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 4.00 |
|---|---|
| High | 4.14 |
| Low | 3.89 |
| Bid | 4.08 |
| Offer | 4.16 |
| Previous close | 3.99 |
| Average volume | 139.53k |
|---|---|
| Shares outstanding | 24.54m |
| Free float | 18.64m |
| P/E (TTM) | -- |
| Market cap | 98.18m USD |
| EPS (TTM) | -3.25 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
- Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
- Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
- Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
- Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
- Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
- Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
- Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
- Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
- Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
More ▼
